89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.
Two tiny genetic variations can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment, according to a genome-wide association study (GWAS) published online July 24 in
Nature Medicine. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most susceptible to long-term damage.
Written by C.P. Kaiser
While PET/CT is commonly and very successfully used for the staging and follow-up of cancers, researchers are seeking ways to make the modality more sensitive and specific by using targeted radiotracers and refining scanning techniques.
Responsible for 2.1 million injuries and 50,000 deaths annually in the U.S., traumatic brain injury (TBI) is the leading cause of death in individuals under the age of 35. The incidence among deployed soldiers is also high, with one study suggesting as many as 300,000 Iraq and Afghanistan veterans have some form of TBI.
New anti-tumor agents result in significant benefits for cancer patients, but may have serious cardiovascular side effects which can be detected early using scintigraphic techniques, according to an article published in the April issue of the Journal of Nuclear Medicine.
Nanotechnology may open a new opportunity for the treatment of liver cancer, according to researchers from Penn State College of Medicine in Hershey, Penn., who used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.
RSS 
